View this email in your browser
Issue 01  |   February 2016
ESL Biosciences, in partnership with Euroimmun AG, offer the most
comprehensive range of allergy-associated diagnostic products


Euroline DPA-Dx

Component-based multiparameter test for allergies

Euroimmun offers over 60 different allergen component Defined Partial Allergen Diagnostics (DPA-Dx) tests, including pollen allergies, food allergies in children, and insect venom allergies.

The molecular allergology immunoblot tests are fast and simple to perform, and are suitable for use in any diagnostic laboratory.  

Test procedure is based on established Euroline technology and consists of three steps: serum incubation, conjugate incubation, and chromogen substrate incubation.  

The tests may be carried out manually, but automated processing may be carried out with the EuroblotOne instrument.  The compact, tabletop device has a high walkaway capacity, with up to 44 strips of varying tests incubated per run.  Dilution, incubation, and washing steps are all automated, and barcode capabilities allow for complete traceability.  Test strips are digitised in a special camera module, and results automatically evaluated.  Integration to LIS software is simple.

Click here to find out more about Euroimmun's immunoblot automation options.

The Euroline system offers a very competitive price per allergen, making this system the ideal choice for labs wanting state-of-the-art allergy diagnostics on a small budget.
This short video demonstrates the abilities of the EuroBlotOne instrument
DPA-Dx Peanut 1 available soon

DPA-Dx Peanut 1
DPA-Dx allow for the determination of specific IgE against single allergen components in serum.  Such precise analysis of allergen-causing components allows for simple, quick patient diagnosis and management.

The DPA-Dx Peanut 1 test allows differentiation between true peanut allergies (Ara h1-9) and pollen-associated cross reactions (Bet v1).  

With low risk component sensitisations (such as Ara h5 and Bet v1/Ara h8), patients can be given targeted dietary advice to avoid unnecessary dietary restrictions.  With high risk component sensitisations (such as Ara h2), well-informed risk assessments can be made.  

By identifying the allergy inducing component of the peanut, patient suitability for specific immunotherapy may be determined. 
Contact Australia
Contact NZ
Copyright © 2016 ESL Biosciences (Australia) P/L. All rights reserved.